Clinical trial
Human Chorionic Gonadotropin Levels After Ovulation Triggering as Predictors of Intracytoplasmic Sperm Injection Outcome
Name
MD.20.09.370
Description
This study aimed to assess the correlation between HCG levels after ovulation triggering and ICSI outcomes, affected by HCG formulation and dose
Trial arms
Trial start
2021-03-31
Estimated PCD
2022-07-19
Trial end
2022-08-07
Status
Completed
Treatment
uHCG
Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
Arms:
uHCG group
Other names:
Choriomon
rHCG
Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
Arms:
rHCG group
Other names:
Ovitrelle
uHCG and GnRHa
Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
Arms:
Dual trigger group
Other names:
Decapeptyl and Choriomon
Size
100
Primary endpoint
Clinical pregnancy rate
6 weeks after embryo transfer
Eligibility criteria
Inclusion Criteria:
* Women who will undergo controlled ovarian stimulation (COS) through fixed GnRH antagonist protocol
Exclusion Criteria:
* BMI \> 30 kg/m2
* Irregular menstruation
* Severe male factor abnormality
* Poor ovarian reserve
* Endometriosis
* Uterine abnormality
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 100, 'type': 'ACTUAL'}}
Updated at
2023-08-01
1 organization
3 products
1 indication
Organization
Mansoura UniversityProduct
uHCGIndication
infertilityProduct
rHCGProduct
uHCG and GnRHa